Collegium Pharmaceutical, Inc. (NASDAQ:COLL) showcases a Return on Invested Capital (ROIC) of 10.34%, significantly outperforming its Weighted Average Cost of Capital (WACC) of 5.18%.Amphastar Pharmaceuticals and Syndax Pharmaceuticals demonstrate lower efficiency in capital utilization compared to Collegium, with Amphastar barely generating returns above its cost of capital.Ironwood Pharmaceuticals exhibits the highest efficiency with a ROIC of 62.21% and a WACC of 6.21%, indicating exceptional capital man ...

Company Overview - Vivos Therapeutics, Inc. (VVOS) is expected to report a quarterly loss of $0.44 per share, reflecting a year-over-year change of +73% [3] - Revenues are anticipated to be $3.7 million, which is an increase of 8.2% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 14.71% lower in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Vivos is the same as the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, but its predictive power is significant mainly for positive readings [7] - Vivos currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat [11] Historical Performance - In the last reported quarter, Vivos was expected to post a loss of $0.43 per share but actually reported a loss of $0.28, resulting in a surprise of +34.88% [12] - Over the past four quarters, Vivos has beaten consensus EPS estimates two times [13] Industry Comparison - Ironwood Pharmaceuticals (IRWD), another player in the Zacks Medical - Drugs industry, is expected to report a loss of $0.05 per share, indicating a year-over-year change of -150% [17] - Ironwood's revenues are projected to be $59.45 million, down 20.6% from the previous year [17] - The consensus EPS estimate for Ironwood has been revised 28.6% lower in the last 30 days, with an Earnings ESP of -121.05% [18]

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.64%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.36 per share when it actually produced a loss of $0.53, delivering a surprise of -47.22%.Over the last four quarters ...